MedTrace Logo

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

NCT06086912 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-02-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.

Conditions

Interventions

DRUG

HR17031

Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).

DRUG

HR17031

Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).

DRUG

HR17031

Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2023-12-12
Completion
2023-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086912 on ClinicalTrials.gov